ArticleBMC public health2021
Rhinovirus prevalence as indicator for efficacy of measures against SARS-CoV-2.
Article in BMC public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Post-COVID-19 resurgence of respiratory viruses in Taiwan: an interrupted time series analysis from three regional medical centers (2015-2023).BMC infectious diseases · 2025Article
- Subacute Thyroiditis-Is it Really Linked to Viral Infection?The Journal of clinical endocrinology and metabolism · 2025Article
- Respiratory virus circulation during pandemic: Why were some viruses still circulating?Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Review
- Impacts of human mobility on the citywide transmission dynamics of 18 respiratory viruses in pre- and post-COVID-19 pandemic years.Nature communications · 2024Article
- Influence of non-pharmaceutical interventions during the COVID-19 pandemic on respiratory viral infections - a prospective population-based cohort study.Frontiers in public health · 2024Article
- Respiratory virus circulation during the first year of the COVID-19 pandemic in the Household Influenza Vaccine Evaluation (HIVE) cohort.Influenza and other respiratory viruses · 2023Article
- The effects of the COVID-19 pandemic on community respiratory virus activity.Nature reviews. Microbiology · 2023Review
- Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022.JAMA network open · 2022Article
- Impact of rhinovirus on hospitalization during the COVID-19 pandemic: A prospective cohort study.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Article
- Effects of COVID-19 and Social Distancing on Rhinovirus Infections and Asthma Exacerbations.Viruses · 2022Review
- Rhinovirus Incidence Rates Indicate We Are Tired of Non-pharmacological Interventions Against Coronavirus Disease 2019.Journal of Korean medical science · 2022Article
- Fewer Bronchiectasis Exacerbations during the "Lockdown" for COVID-19: Can We Convert Knowledge into Action?American journal of respiratory and critical care medicine · 2021Article
- Clinical Characteristics of Pediatric Respiratory Tract Infection and Respiratory Pathogen Isolation During the Coronavirus Disease 2019 Pandemic.Frontiers in pediatrics · 2021Article
- Investigating the human rhinovirus co-infection in patients with asthma exacerbations and COVID-19.Pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNon-pharmaceutical measures to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should be carefully tuned as they can impose a heavy social and economic burden. To quantify and possibly tune the efficacy of these anti-SARS-CoV-2 measures, we have devised indicators based on the abundant historic and current prevalence data from other respiratory viruses.
methodsWe obtained incidence data of 17 respiratory viruses from hospitalized patients and outpatients collected by 37 clinics and laboratories between 2010-2020 in Germany. With a probabilistic model for Bayes inference we quantified prevalence changes of the different viruses between months in the pre-pandemic period 2010-2019 and the corresponding months in 2020, the year of the pandemic with noninvasive measures of various degrees of stringency.
resultsWe discovered remarkable reductions δ in rhinovirus (RV) prevalence by about 25% (95% highest density interval (HDI) [-0.35,-0.15]) in the months after the measures against SARS-CoV-2 were introduced in Germany. In the months after the measures began to ease, RV prevalence increased to low pre-pandemic levels, e.g. in August 2020 δ=-0.14 (95% HDI [-0.28,0.12]).
conclusionsRV prevalence is negatively correlated with the stringency of anti-SARS-CoV-2 measures with only a short time delay. This result suggests that RV prevalence could possibly be an indicator for the efficiency for these measures. As RV is ubiquitous at higher prevalence than SARS-CoV-2 or other emerging respiratory viruses, it could reflect the efficacy of noninvasive measures better than such emerging viruses themselves with their unevenly spreading clusters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.